SCHEMBL2453162

SCHEMBL2453162

O=C(Cc1ccsc1)Nc1cc(Oc2ccc3nc(NC(=O)C4CC4)sc3n2)ccc1F

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.66
RIPK3 Q9Y572 16/20 0.59
RIPK1 Q13546 16/20 0.59
KDR P35968 3/20 0.58
CHEK1 O14757 1/20 0.52
IKBKB O14920 1/20 0.52
RAF1 P04049 1/20 0.52
PDGFA P04085 1/20 0.52
CDK1 P06493 1/20 0.52
PDGFRB P09619 1/20 0.52
CCNB1 P14635 1/20 0.52
CCNA2 P20248 1/20 0.52
FGFR3 P22607 1/20 0.52
CDK2 P24941 1/20 0.52
GSK3B P49841 1/20 0.52
MAP2K1 Q02750 1/20 0.52
TEK Q02763 1/20 0.52
MAPK14 Q16539 1/20 0.52
AURKB Q96GD4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2453065 0.87 BRAF (0.67) BRAFRIPK3RIPK1KDRCHEK1
SCHEMBL2453182 0.85 RIPK1 (0.80) BRAFRIPK3RIPK1KDRCHEK1
SCHEMBL2851381 0.84 BRAF (0.77) BRAFRIPK3RIPK1KDRPDGFRB
SCHEMBL2452621 0.82 RIPK1 (0.70) BRAFRIPK3RIPK1KDRCHEK1
SCHEMBL16504285 0.81 RIPK3 (0.64) BRAFRIPK3RIPK1KDRCHEK1
SCHEMBL12333393 0.79 RAB9A (0.49) BRAFRIPK3RIPK1KDRPDGFRB
SCHEMBL16994980 0.79 RIPK1 (0.44) BRAFRIPK3RIPK1KDRCHEK1
SCHEMBL2453008 0.78 BRAF (0.69) BRAFRIPK3RIPK1KDRPDGFRB
SCHEMBL2452667 0.78 BRAF (0.65) BRAFRIPK3RIPK1KDRCHEK1
SCHEMBL12333868 0.78 BRAF (0.63) BRAFRIPK3RIPK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2399921-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-08-12 EP disclosed
US-8697874-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-15 US disclosed
EP-2399921-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-12-28 EP disclosed
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-29 US disclosed
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-29 US disclosed
WO-2010064611-A1 HETEROCYCLIC COMPOUND AND USE THEREOF 武田薬品工業株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NR3C2, RAF1 BRAF 1/4885RIPK3 705/4885RIPK1 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.